The stocks of GSK will be posting a sales sum of $10.72 billion for this quarter, according to major predictions from brokerage firms. Two of the analysts covering the firm have already given estimates into the earnings of the company. The ball has been rolled at $10.61 billion, all the way to $10.83 billion. Just the previous year, the pharmaceutical company had posted a sales sum of $9.46 billion, which implies an annual growth rate of about 13.3%. The company will be posting its next quarterly sum on the 4th of August.
The Quarterly Estimates Of GSK
GSK did post their quarterly earnings on the 2nd of February. The company had reported an EPS of $0.62 for the quarter, as it barely missed out on the consensus of $0.64. The return on equity for the company was 29.60%, with an 18.50% net margin. The revenue generated by the company during this period was $8.74 billion, with the consensus estimate coming in at $8.71 billion.
There have been quite a few research equities that have commented on the stocks of GSK. Berenberg Bank has already put up a rating of buy in an 11th February research report. SVB Leerink has also reiterated their rating of market perform in a 29th March research report. Zacks Investment Research has also increased the rating of the company from strong sell to hold with a price target of $40 in a 20th April research report. UBS Group has reaffirmed its rating of neutral in a 20th April research report.
Three of the investment analysts covering the firm have given it a rating of sell, while five others have given it a rating of hold. Currently, GSK enjoys a hold rating with a $40 price target.